Refining the treatment of follicular lymphoma

Leukemia and Lymphoma

Volumn 49, Issue SUPPL. 1, 2008, Pages 18-26

  Buske, Christian ^a   Gisselbrecht, Christian ^b   Gribben, John ^c   Letai, Tony ^d   McLaughlin, Peter ^e   Wilson, Wyndham ^f  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b SAINT LOUIS HOSPITAL   (France)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Biological factors; FLIPI; Follicular lymphoma; Novel treatments; Rituximab

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ABT 263; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BH3 PROTEIN; CD68 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; PROTEIN BCL 2; RITUXIMAB; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; VINCRISTINE;

ARTICLE; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ASSESSMENT TOOL; CLINICAL PROTOCOL; DECISION MAKING; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG SENSITIVITY; EARLY INTERVENTION; FOLLICULAR LYMPHOMA; FOLLICULAR LYMPHOMA INTERNATIONAL PROGNOSTIC INDEX; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENE TARGETING; GENETIC MARKER; HIGH RISK PATIENT; HUMAN; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; WATCHFUL WAITING;

BIOLOGICAL MARKERS; DECISION MAKING, COMPUTER-ASSISTED; DIAGNOSIS, COMPUTER-ASSISTED; HUMANS; LYMPHOMA, FOLLICULAR; PROGNOSIS;

EID: 53349142066     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190802311409     Document Type: Article

References (58)

1. Liu, Q., Fayad, L., Cabanillas, F., Hagemeister, F. B., Ayers, G. D. Hess, M. et al. (2006) Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol, 24, pp. 1582-1589.
2. Fisher, R. I., LeBlanc, M., Press, O. W., Maloney, D. G., Unger, J. M. and Miller, T. P. (2005) New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol, 23, pp. 8447-8452.
3. van Oers, M. H. (2007) Rituximab maintenance therapy: A step forward in follicular lymphoma. Haematologica, 92, pp. 826-833.
4. Forstpointner, R., Dreyling, M., Repp, R., Hermann, S., Hanel, A. Metzner, B. et al. (2004) The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood, 104, pp. 3064-3071.
5. Solal-Celigny, P., Roy, P., Colombat, P., White, J., Armitage, J. O. Arranz-Saez, R. et al. (2004) Follicular lymphoma international prognostic index. Blood, 104, pp. 1258-1265.
6. Foussard, C., Mounier, N., Van Hoof, A., Delwail, V., Casasnovas, O. Deconinck, E. et al. (2006) Update of the FL2000 randomized trial combining rituximab to CHVP-Interferon in follicular lymphoma (FL) patients (pts). J Clin Oncol, 24, p. 7508.
7. Herold, M., Haas, A., Srock, S., Neser, S., Al-Ali, K. H. Neubauer, A. et al. (2007) Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: An East German Study Group Hematology and Oncology Study. J Clin Oncol, 25, pp. 1986-1992.
8. Hiddemann, W., Kneba, M., Dreyling, M., Schmitz, N., Lengfelder, E. Schmits, R. et al. (2005) Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood, 106, pp. 3725-3732.
9. Marcus, R., Imrie, K., Belch, A., Cunningham, D., Flores, E. Catalano, J. et al. (2005) CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood, 105, pp. 1417-1423.
10. Buske, C., Hoster, E., Dreyling, M., Hasford, J., Unterhalt, M. and Hiddemann, W. (2006) The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood, 108, pp. 1504-1508.
11. McLaughlin, P., Fuller, L. M., Velasquez, W. S., Sullivan-Halley, J. A., Butler, J. J. and Cabanillas, F. (1986) Stage I-II follicular lymphoma. Treatment results for 76 patients. Cancer, 58, pp. 1596-1602.
12. Besa, P. C., McLaughlin, P. W., Cox, J. D. and Fuller, L. M. (1995) Long term assessment of patterns of treatment failure and survival in patients with stage I or II follicular lymphoma. Cancer, 75, pp. 2361-2367.
13. Plancarte, F., Lopez-Guillermo, A., Arenillas, L., Montoto, S., Gine, E. Muntanola, A. et al. (2006) Follicular lymphoma in early stages: High risk of relapse and usefulness of the Follicular Lymphoma International Prognostic Index to predict the outcome of patients. Eur J Haematol, 76, pp. 58-63.
14. Seymour, J. F., Pro, B., Fuller, L. M., Manning, J. T., Hagemeister, F. B. Romaguera, J. et al. (2003) Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma. J Clin Oncol, 21, pp. 2115-2122.
15. Damaj, G., Verkarre, V., Delmer, A., Solal-Celigny, P., Yakoub-Agha, I. Cellier, C. et al. (2003) Primary follicular lymphoma of the gastrointestinal tract: A study of 25 cases and a literature review. Ann Oncol, 14, pp. 623-629.
16. Goodlad, J. R., Krajewski, A. S., Batstone, P. J., McKay, P., White, J. M. Benton, E. C. et al. (2002) Primary cutaneous follicular lymphoma: A clinicopathologic and molecular study of 16 cases in support of a distinct entity. Am J Surg Pathol, 26, pp. 733-741.
17. Zelenetz, A. D., Advani, R. H., Glenn, M. J., Bociek, R. G., Buadi, F. Caligiuri, M. A. et al. NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin's Lymphoma V3.
18. Guadagnolo, B. A., Li, S., Neuberg, D., Ng, A., Hua, L. Silver, B. et al. (2006) Long-term outcome and mortality trends in early-stage, Grade 1-2 follicular lymphoma treated with radiation therapy. Int J Radiat Oncol Biol Phys, 64, pp. 928-934.
19. MacManus, M. P. and Hoppe, R. T. (1996) Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol, 14, pp. 1282-1290.
20. Petersen, P. M., Gospodarowicz, M., Tsang, R., Pintilie, M., Wells, W. Hodgson, D. et al. (2004) Long-term outcome in stage I and II follicular lymphoma following treatment with involved field radiation. J Clin Oncol, 22, p. 6521.
21. Soubeyran, P., Eghbali, H., Trojani, M., Bonichon, F., Richaud, P. and Hoerni, B. (1996) Is there any place for a wait-and-see policy in stage I0 follicular lymphoma? A study of 43 consecutive patients in a single center. Ann Oncol, 7, pp. 713-718.
22. Tezcan, H., Vose, J. M., Bast, M., Bierman, P. J., Kessinger, A. and Armitage, J. O. (1999) Limited stage I and II follicular non-Hodgkin's lymphoma: The Nebraska Lymphoma Study Group experience. Leuk Lymphoma, 34, pp. 273-285.
23. Jaffe, E. S., Harris, N. L., Stein, H. and Vardiman, J. W. (2001) World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon, France
24. Winter, J. N., Gascoyne, R. D. and Van, B. K. (2004) Low-grade lymphoma. Hematology Am Soc Hematol Educ Program.pp. 203-220.
25. Ganti, A. K., Weisenburger, D. D., Smith, L. M., Hans, C. P., Bociek, R. G. Bierman, P. J. et al. (2006) Patients with grade 3 follicular lymphoma have prolonged relapse-free survival following anthracycline-based chemotherapy: The Nebraska Lymphoma Study Group Experience. Ann Oncol, 17, pp. 920-927.
26. Hans, C. P., Weisenburger, D. D., Vose, J. M., Hock, L. M., Lynch, J. C. Aoun, P. et al. (2003) A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival. Blood, 101, pp. 2363-2367.
27. Tilly, H., Rossi, A., Stamatoullas, A., Lenormand, B., Bigorgne, C. Kunlin, A. et al. (1994) Prognostic value of chromosomal abnormalities in follicular lymphoma. Blood, 84, pp. 1043-1049.
28. Weisenburger, D. D., Anderson, J. R., Diebold, J., MacLennan, K. A. Muller-Hermelink, H. K. et al. (1998) Grading of follicular lymphoma: diagnostic accuracy, reproducibility and clinical relevance. Mod Pathol, 11, p. 142.
29. Wendum, D., Sebban, C., Gaulard, P., Coiffier, B., Tilly, H. Cazals, D. et al. (1997) Follicular large-cell lymphoma treated with intensive chemotherapy: An analysis of 89 cases included in the LNH87 trial and comparison with the outcome of diffuse large B-cell lymphoma. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol, 15, pp. 1654-1663.
30. Rodriguez, J., McLaughlin, P., Hagemeister, F. B., Fayad, L., Rodriguez, M. A. Santiago, M. et al. (1999) Follicular large cell lymphoma: An aggressive lymphoma that often presents with favorable prognostic features. Blood, 93, pp. 2202-2207.
31. Krishnan, A., Nademanee, A., Fung, H., Angelopoulou, M., Molina, A. Gaal, K. et al. (2006) Does follicularity in large cell lymphoma predict outcome after autologous stem cell transplantation?. Biol Blood Marrow Transplant, 12, pp. 641-647.
32. Certo, M., Del Gaizo Moore, V, Nishino, M., Wei, G., Korsmeyer, S. Armstrong, S. A. et al. (2006) Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell, 9, pp. 351-365.
33. Del Gaizo Moore, V, Brown, J. R., Certo, M., Love, T. M., Novina, C. D. and Letai, A. (2007) Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest, 117, pp. 112-121.
34. Deng, J., Carlson, N., Takeyama, K., Dal, C. P., Shipp, M. and Letai, A. (2007) BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell, 12, pp. 171-185.
35. Mason, K. D., Carpinelli, M. R., Fletcher, J. I., Collinge, J. E., Hilton, A. A. Ellis, S. et al. (2007) Programmed anuclear cell death delimits platelet life span. Cell, 128, pp. 1173-1186.
36. Nakayama, K., Nakayama, K., Negishi, I., Kuida, K., Sawa, H. and Loh, D. Y. (1994) Targeted disruption of Bcl-2 alpha beta in mice: Occurrence of gray hair, polycystic kidney disease, and lymphocytopenia. Proc Natl Acad Sci USA, 91, pp. 3700-3704.
37. Print, C. G., Loveland, K. L., Gibson, L., Meehan, T., Stylianou, A. Wreford, N. et al. (1998) Apoptosis regulator bcl-w is essential for spermatogenesis but appears otherwise redundant. Proc Natl Acad Sci USA, 95, pp. 12424-12431.
38. Wagner, K. U., Claudio, E., Rucker EB, I II, Riedlinger, G., Broussard, C. Schwartzberg, P. L. et al. (2000) Conditional deletion of the Bcl-x gene from erythroid cells results in hemolytic anemia and profound splenomegaly. Development, 127, pp. 4949-4958.
39. Wilson, W. H., Tulpule, A., Levine, A. M., Dunleavy, K., Krivoshik, A. P. Hagey, A. E. et al. (2007) A phase 1/2a study evaluating the safety, pharmacokinetics, and efficacy of ABT-263 in subjects with refractory or relapsed lymphoid malignancies. Blood, 110, p. 1371.
40. Dave, S. S., Wright, G., Tan, B., Rosenwald, A., Gascoyne, R. D. Chan, W. C. et al. (2004) Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med, 351, pp. 2159-2169.
41. de Jong, D. (2005) Molecular pathogenesis of follicular lymphoma: A cross talk of genetic and immunologic factors. J Clin Oncol, 23, pp. 6358-6363.
42. Alvaro, T., Lejeune, M., Salvado, M. T., Lopez, C., Jaen, J. Bosch, R. et al. (2006) Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. J Clin Oncol, 24, pp. 5350-5357.
43. Alvaro, T., Lejeune, M., Camacho, F. I., Salvado, M. T., Sanchez, L. Garcia, J. F. et al. (2006) The presence of STAT1-positive tumor-associated macrophages and their relation to outcome in patients with follicular lymphoma. Haematologica, 91, pp. 1605-1612.
44. Cerhan, J. R., Wang, S., Maurer, M. J., Ansell, S. M., Geyer, S. M. Cozen, W. et al. (2007) Prognostic significance of host immune gene polymorphisms in follicular lymphoma survival. Blood, 109, pp. 5439-5446.
45. Farinha, P., Masoudi, H., Skinnider, B. F., Shumansky, K., Spinelli, J. J. Gill, K. et al. (2005) Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood, 106, pp. 2169-2174.
46. Lee, A. M., Clear, A. J., Calaminici, M., Davies, A. J., Jordan, S. MacDougall, F. et al. (2006) Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome. J Clin Oncol, 24, pp. 5052-5059.
47. Carreras, J., Lopez-Guillermo, A., Fox, B. C., Colomo, L., Martinez, A. Roncador, G. et al. (2006) High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood, 108, pp. 2957-2964.
48. Farinha, P., Han, J., Al-Tourah, A., Connors, J. M., Banerjee, D. and Gascoyne, R. (2006) The tumor microenvironment measured by flow cytometry predicts overall survival (OS) and transformation risk (TR) in follicular lymphoma. Blood, 108, p. 2406.
49. Glas, A. M., Knoops, L., Delahaye, L., Kersten, M. J., Kibbelaar, R. E. Wessels, L. A. et al. (2007) Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. J Clin Oncol, 25, pp. 390-398.
50. Ai, W YZ, Czerwinski, D., Horning, S. J., Allen, J., Tibshirani, R. and Levy, R. (2006) Tumor-infiltrating T cells are not predictive of clinical outcome in follicular lymphoma. Blood, 108, p. 824.
51. Wahlin, B. E., Sander, B., Christensson, B. and Kimby, E. (2007) CD8+ T-cell content in diagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma. Clin Cancer Res, 13, pp. 388-397.
52. Yang, Z. Z., Novak, A. J., Ziesmer, S. C., Witzig, T. E. and Ansell, S. M. (2006) Attenuation of CD8(+) T-cell function by CD4(+)CD25(+) regulatory T cells in B-cell non-Hodgkin's lymphoma. Cancer Res, 66, pp. 10145-10152.
53. Horning, S. J. (1987) Durable remissions in stage III follicular lymphoma: Interpret with caution. J Clin Oncol, 5, pp. 838-839.
54. Anderson, J. R., Vose, J. M., Bierman, P. J., Weisenberger, D. D., Sanger, W. G. Pierson, J. et al. (1993) Clinical features and prognosis of follicular large-cell lymphoma: A report from the Nebraska Lymphoma Study Group. J Clin Oncol, 11, pp. 218-224.
55. Bartlett, N. L., Rizeq, M., Dorfman, R. F., Halpern, J. and Horning, S. J. (1994) Follicular large-cell lymphoma: Intermediate or low grade?. J Clin Oncol, 12, pp. 1349-1357.
56. Miller, T. P., LeBlanc, M., Grogan, T. M. and Fisher, R. I. (1997) Follicular lymphomas: Do histologic subtypes predict outcome?. Hematol Oncol Clin North Am, 11, pp. 893-900.
57. Rodriguez, J., McLaughlin, P., Fayad, L., Santiago, M., Hess, M. Rodriguez, M. A. et al. (2000) Follicular large cell lymphoma: Long-term follow-up of 62 patients treated between 1973-1981. Ann Oncol, 11, pp. 1551-1556.
58. Chau, I., Jones, R., Cunningham, D., Wotherspoon, A., Maisey, N. Norman, A. R. et al. (2003) Outcome of follicular lymphoma grade 3: Is anthracycline necessary as front-line therapy?. Br J Cancer, 89, pp. 36-42.